Back of the envelope calculation for Rintega reimbursement to CLDX:
- cost of $10,000/pt/course of treatment
- all vIII GBM become relapsed/refractory at some point
- steady state number of rGBM ~3,000 pts/yr
- $10,000 x 3000= $30M/yr
It would help with the burn rate, don't see it as a game changer.
The deal of the century?
Celldex scooped up Glembat in 2009 with the $93.5 million acquisition of CuraGen, which had a cash balance of $53.5 million at the deal's close, and added CuraGen's CEO, Dr. Timothy Shannon, to Celldex's board of directors. If Glembat's previous results are confirmed in the ongoing "Metric" trial, which is expected to complete enrollment by end of the year, then Celldex intends to file an application.
If Glembat is approved, the triple-negative breast-cancer population alone could push the drug into $1 billion annual sales -- "blockbuster" territory. Investigator-sponsored trials in some rare cancers, and ongoing melanoma investigations, could expand its use even further.
Celldex's purchase of CuraGen could be the deal of the century. If Glembat succeeds, it would give Celldex the resources to advance other pipeline assets. It's early yet, but Celldex's immuno-oncology candidate varlilumab is in combination studies with Bristol-Myers Squibb's Opdivo and Roche's recently approved Tecentriq. Should one of these combinations or Celldex's earlier-stage candidates score, this could become one of the best-performing stocks in these billionaire money-managers' portfolios.